




2020 HEDIS[®] COMPLIANCE

Coding Tools



Prepared by The Quality, Strategy and Performance Operations Team: UnitedHealthcare, HPN Quality Improvement.
 Source: NCQA HEDIS[®] 2019 Technical Specifications, Volume 2.
 HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).

HEDIS® CODING OPPORTUNITIES

Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB)
Percentage of members ages 18-64 with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription.
Negative Medication History
Inverted rate; proportion for whom antibiotics were <i>not</i> prescribed.

Adult Body Mass Index Assessment (ABA)
Percentage of members ages 18-74 who had an outpatient visit and whose body mass index (BMI) was documented during the measurement year or the year prior to the measurement year.
ICD-10 Diagnosis
BMI % Z68.51, Z68.52, Z68.53, Z68.54
Body Mass Index Z68.1, Z68.20, Z68.21, Z68.22, Z68.23, Z68.25, Z68.25, Z68.26, Z68.27, Z68.29, Z68.30, Z68.31, Z68.32, Z68.33, Z68.34, Z68.35, Z68.36, Z68.37, Z68.38, Z68.39, Z68.41, Z68.42, Z68.43, Z68.44, Z68.45

Follow-Up Care for Children Prescribed ADHD Medication (ADD)	
Percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed.	
CPT/CPT II	
Stand-Alone Visits 96150-54, 98960-62, 99078, 99201-05, 99211-15, 99217-20, 99241-45, 99341-45, 99347-50, 99381-84, 99391-94, 99401-04, 99411-12, 99510	
Telephone Visits 98966-68, 99441-43	
HCPCS	
Stand-Alone Visits G0155, G0176-77, G0409-11, G0463, H0002, H0004, H0031, H0034-37, H0039-40, H2000-01, H2010-20, M0064, S0201, S9480, S9484-85, T1015	
UBREV	
Stand-Alone Visits 0510, 0513, 0515, 0516, 0517, 0519, 0520, 0521, 0522, 0523, 0526, 0527, 0528, 0529, 0900, 0902, 0903, 0904, 0905, 0907, 0911, 0912, 0913, 0914, 0915, 0916, 0917, 0919, 0982, 0983	
Scenario 1	
CPT/CPT II AND	Place of Service Codes/Location
Group Visits 90791-92,	03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17,

90832-34, 90836-40, 90845, 90847, 90849, 90853, 90857, 90876	18, 19, 20, 22,33, 49, 50, 52, 53, 71, 72
Scenario 2	
CPT/CPT II AND	Place of Service Codes/Location
Group Visits 99221-23, 99231-33, 99238-39, 99251-55	52, 53
Scenario 3	
CPT/CPT II AND	CPT/CPT II Modifier
Group Visits 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90857, 90876	Telehealth Modifier 95, GT
Scenario 4	
CPT/CPT II AND	CPT/CPT II Modifier
Group Visits 99221-23, 99231-33, 99238-39, 99251-55	Telehealth Modifier 95, GT

Antidepressant Medication Management (AMM)	
Percentage of members ages 18 and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment.	
Antidepressant Medications (RXNORM codes)	
Miscellaneous antidepressants	<ul style="list-style-type: none"> <li style="margin-right: 10px;">• Bupropion <li style="margin-right: 10px;">• Vilazodone • Vortiozetine
Monoamine oxidase inhibitors	<ul style="list-style-type: none"> <li style="margin-right: 10px;">• Isocarboxazid <li style="margin-right: 10px;">• Selegiline • Phenelzine • Tranylcypromine
Phenylpiperazine antidepressants	<ul style="list-style-type: none"> <li style="margin-right: 10px;">• Nefazodone • Trazodone
Psychotherapeutic combinations	<ul style="list-style-type: none"> • Amitriptyline-chlordiazepoxide • Amitriptyline-perphenazine • Fluoxetine-olanzapine
SNRI antidepressants	<ul style="list-style-type: none"> <li style="margin-right: 10px;">• Desvenlafaxine <li style="margin-right: 10px;">• Venlafaxine • Duloxetine • Levomilnacipran
SSRI antidepressants	<ul style="list-style-type: none"> <li style="margin-right: 10px;">• Citalopram <li style="margin-right: 10px;">• Fluoxetine <li style="margin-right: 10px;">• Paroxetine • Escitalopram • Fluvoxamine • Sertraline

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Tetracyclic antidepressants	• Maprotiline	• Mirtazapine	
Tricyclic antidepressants	• Amitriptyline	• Desipramine	• Nortriptyline
	• Amoxapine	• Doxepine	• Protriptyline
	• Clomipramine	• Imipramine	• Trimipramine

Asthma Medication Ratio (AMR)			
Percentage of members ages 5-64 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.			
Asthma Controller Medications			
Antiasthmatic combinations	•Dyphylline-guaifenesin •Guaifenesin-theophylline		
Antibody inhibitors	•Omalizumab		
Anti-interleukin-5	•Mepolizumab	•Reslizumab	
Inhaled steroid combinations	•Budesonide-formoterol	•Fluticasone-vilanterol	
	• Fluticasone-salmeterol	•Mometasone-formoterol	
Inhaled corticosteroids	•Beclomethasone	•Ciclesonide	•Fluticasone
	• Budesonide	• Flunisolide	• Mometasone
Leukotriene modifiers	•Montelukast	•Zafirlukast	•Zileuton
Methylxanthines	•Dyphylline	•Theophylline	
Asthma Reliever Medications			
Short-acting, inhaled beta-2 agonists	•Albuterol	•Pirbuterol	
	•Levalbuterol		

Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)			
Percentage of children and adolescents ages 1-17 who were on two or more concurrent antipsychotic medications for at least 90 consecutive days during the measurement year.			
Antipsychotic Medications			
Miscellaneous	• Aripiprazole	• Iloperidone	• Pimozide

antipsychotic agents	• Asenapine	• Loxapine	• Quetiapine
	• Brexpiprazole	• Lurisdalone	• Quetiapine fumarate
	• Cariprazine	• Molindone	• Risperidone
	• Clozapine	• Olanzapine	• Ziprasidone
	• Haloperidol	• Paliperidone	
Phenothiazine antipsychotics	•Chlorpromazine	• Perphenazine-amitriptyline	• Thioridazine
	• Fluphenazine	•Prochlorperazine	•Trifluoperazine
Thioxanthenes	• Thiothixene		
Long-acting injections	• Aripiprazole		• Olanzapine
	• Fluphenazine decanoate		• Paliperidone palmitate
	• Haloperidol decanoate		• Risperidone

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	
Percentage of children and adolescents ages 1-17 who had two or more antipsychotic prescriptions and had metabolic testing.	
CPT/CPT II	
Glucose Test	80047-48, 80050, 80053, 80069, 82947, 82950-51
HbA1c Test	83036-37, 3044F-46F
Cholesterol Test Other Than LDL	82465, 83718, 84478
LDL-C Test	80061, 83700-01, 83704, 83721, 3048F-50F
LOINC	
Glucose Test	10450-5, 1492-8, 1494-4, 1496-9, 1499-3, 1501-6, 1504-0, 1507-3, 1514-9, 1518-0, 1530-5, 1533-9, 1554-5, 1557-8, 17865-7, 20436-2, 20437-0, 20438-8, 20440-4, 26554-6, 41024-1, 6749-6, 9375-7
HbA1c Test	17856-6, 4548-4, 4549-2
Cholesterol Test Other Than LDL	2085-9, 2093-3, 2571-8, 3043-7, 9830-1
LDL-C Test	12773-8, 13457-7, 18261-8, 18262-6, 2089-1, 49132-4, 55440-2

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)			
Percentage of children and adolescents 1-17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as a first-line treatment.			
Antipsychotic Medications			
Miscellaneous antipsychotic agents	<ul style="list-style-type: none"> • Aripiprazole • Asenapine • Brexpiprazole • Cariprazine • Clozapine • Haloperidol 	<ul style="list-style-type: none"> • Iloperidone • Loxapine • Lurasidone • Molindone • Olanzapine • Paliperidone 	<ul style="list-style-type: none"> • Pimozide • Quetiapine • Quetiapine fumarate • Risperidone • Ziprasidone
Phenothiazine antipsychotics	<ul style="list-style-type: none"> • Chlorpromazine • Fluphenazine • Perphenazine 	<ul style="list-style-type: none"> • Perphenazine-amitriptyline • Prochlorperazine 	<ul style="list-style-type: none"> • Thioridazine • Trifluoperazine
Thioxanthenes	<ul style="list-style-type: none"> • Thiothixene 		
Long-acting injections	<ul style="list-style-type: none"> • Aripiprazole • Fluphenazine decanoate • Haloperidol decanoate 	<ul style="list-style-type: none"> • Olanzapine • Paliperidone palmitate • Risperidone 	
Antipsychotic Combination Medications			
Psychotherapeutic combinations	<ul style="list-style-type: none"> • Fluoxetine-olanzapine • Perphenazine-amitriptyline 		

Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)
Percentage of members ages 18 and older who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease-modifying and anti-rheumatic drug (DMARD).
HCPCS
DMARD Medications J0129, J0135, J0717, J1438, J1600, J1602, J1745, J3262, J7502, J7515, J7516, J7517, J7518, J9250, J9260, J9310

Adolescent Well-Care Visits (AWC)		
Percentage of members ages 12-21 who had at least one comprehensive well-care visit with a primary care provider or an OB/GYN during the measurement year.		
CPT/CPT II	HCPCS	ICD-10 Diagnosis
Well-Care Visits 99381-85, 99391-95, 99461	Well-Care Visits G0438, G0439	Well-Care Visits Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.5, Z00.8, Z02.0, Z02.1, Z02.2, Z02.3, Z02.4, Z02.5, Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9

Breast Cancer Screening (BCS)		
Percentage of members ages 50-74 who had a mammogram screening Oct. 1 two years prior to the measurement year through Dec. 31 of the measurement year.		
CPT/CPT II	HCPCS	UBREV
Mammography 77055-57, 77061-63, 77065-67	Mammography G0202, G0204, G0206	Mammography 0401, 0403

Controlling High Blood Pressure (CBP)
Percentage of members ages 18-85 who had a diagnosis of hypertension and whose blood pressure was adequately controlled during the measurement year.
CPT/CPT II
Diastolic BP Levels 3078-79F Systolic BP Levels 3074-75 F Remote BP Monitoring 93784, 93788, 93790, 99091

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Cervical Cancer Screening (CCS)		
Percentage of female members ages 21-64 who were screened for cervical cancer: ages 21-64 cervical cytology every three years, ages 30-64 cervical cytology/HPV co-testing every five years.		
CPT/CPT II	HCPCS	LOINC
Cervical Cytology 88141-43, 88147-48, 88150, 88152-54, 88164-67, 88174-75 HPV Test 87620-22, 87624-5	Cervical Cytology G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091 HPV Test G0476	Cervical Cytology 10524-7, 18500-9, 19762-4, 19764-0, 19765-7, 19766-5, 19774-9, 33717-0, 47527-7, 47528-5 HPV Test 21440-3, 30167-1, 38372-9, 59263-4, 59264-2, 59420-0, 69002-4, 71431-1, 75694-0, 77379-6, 77399-4, 77400-0, 82354-2, 82456-5, 82675-0
UBREV		
Cervical Cytology 0923		

Comprehensive Diabetes Care (CDC)- A1C	
Percentage of members ages 18-75 with diabetes who had an HbA1c lab test during the measurement year that showed their blood sugar is under control.	
CPT/CPT II	LOINC
HbA1c Test 83036-37, 3044F-46F HbA1c Level <7 3044F HbA1c Level >9 3046F	HbA1c Test 17856-6, 4548-4, 4549-2

Comprehensive Diabetes Care (CDC)- BP
Percentage of members ages 18-75 with diabetes who have a blood pressure reading of <140/90 mmHg in the measurement year.
CPT/CPT II
Diastolic BP Levels 3078-79F Systolic BP Levels 3074-75F Remote BP Monitoring 93784, 93788, 93790, 99091

Comprehensive Diabetes Care (CDC)- EYE	
Percentage of members ages 18-75 with diabetes who had any one of the following: retinal or dilated eye exam by an optometrist or ophthalmologist in the measurement year, negative retinal or dilated eye exam by an optometrist or ophthalmologist in the year prior to the measurement year.	
CPT/CPT II	HCPCS
Diabetic Eye Exam 67028, 67030-31, 67036, 67039-43, 67101, 67105, 67107-08, 67110, 67112-13, 67121, 67141, 67145, 67208, 67210, 67218, 67220-21, 67227-28, 92002, 92004, 92012, 92014, 92018-19, 92134, 92225-28, 92230, 92235, 92240, 92250, 92260, 99203-05, 99213-15, 99242-45, 2022F, 2024F, 2026F, 3072F	Diabetic Eye Exam S0620, S0621, S3000

Comprehensive Diabetes Care (CDC)- NEPH	
Percentage of members ages 18-75 with diabetes who had medical attention for nephropathy during the measurement year.	
CPT/CPT II	ICD-10 Procedure
Evidence of Treatment for Nephropathy 3066F, 4010F Urine Protein Test 81000-03, 81005, 82042-44, 84156, 3060F-62F	Evidence of Treatment for Nephropathy E08.21, E08.22, E08.29, E09.21, E09.22, E09.29, E10.21, E10.22, E10.29, E11.21, E11.22, E11.29, E13.21, E13.22, E13.29, I12.0, I12.9, I13.0, I13.10, I13.11, I13.2, I15.0, I15.1, N00.0, N00.1, N00.2, N00.3, N00.4, N00.5, N00.6, N00.7, N00.8, N00.9, N01.0, N01.1, N01.2, N01.3, N01.4, N01.5, N01.6, N01.7, N01.8, N01.9, N02.0, N02.1, N02.2, N02.3, N02.4, N02.5, N02.6, N02.7, N02.8, N02.9, N03.0, N03.1, N03.2, N03.3, N03.4, N03.5, N03.6, N03.7, N03.8, N03.9, N04.0, N04.1, N04.2, N04.3, N04.4, N04.5, N04.6, N04.7, N04.8, N04.9, N05.0, N05.1, N05.2, N05.3, N05.4, N05.5, N05.6, N05.7, N05.8, N05.9, N06.0, N06.1, N06.2, N06.3, N06.4, N06.5, N06.6, N06.7, N06.8, N06.9, N07.0, N07.1, N07.2, N07.3, N07.4, N07.5, N07.6, N07.7, N07.8, N07.9, N08, N14.0,

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

	N14.1, N14.2, N14.3, N14.4, N17.0, N17.1, N17.2, N17.8, N17.9, N18.1, N18.2, N18.3, N18.4, N18.5, N18.6, N18.9, N19, N25.0, N25.1, N25.81, N25.89, N25.9, N26.1, N26.2, N26.9, Q60.0, Q60.1, Q60.2, Q60.3, Q60.4, Q60.5, Q60.6, Q61.00, Q61.01, Q61.02, Q61.11, Q61.19, Q61.2, Q61.3, Q61.4, Q61.5, Q61.8, Q61.9, R80.0, R80.1, R80.2, R80.3, R80.8, R80.9
LOINC	
Urine Protein Test 11218-5, 12842-1, 13705-9, 13801-6, 13986-5, 13992-3, 14956-7, 14957-5, 14958-3, 14959-1, 1753-3, 1754-1, 1755-8, 1757-4, 17819-4, 18373-1, 20454-5, 20621-9, 21059-1, 21482-5, 26801-1, 27298-9, 2887-8, 2888-6, 2889-4, 2890-2, 29946-1, 30000-4, 30001-2, 30003-8, 32209-9, 32294-1, 32551-4, 34366-5, 35663-4, 40486-3, 40662-9, 40663-7, 43605-5, 43606-3, 43607-1, 44292-1, 47558-2, 49002-9, 49023-5, 50209-6, 50561-0, 50949-7, 51190-7, 53121-0, 53525-2, 53530-2, 53531-0, 53532-8, 56553-1, 57369-1, 57735-3, 5804-0, 58448-2, 58992-9, 59159-4, 60678-0, 63474-1, 6941-9, 6942-7, 76401-9, 77253-3, 77254-1, 77940-5, 9318-7	

Chlamydia Screening in Women (CHL)	
Percentage of female members ages 16-24 who were identified as sexually active and who had at least one test for chlamydia during the measurement year.	
CPT/CPT II	LOINC
Chlamydia Screening Test 87110, 87270, 87320, 87490-92, 87810	Chlamydia Screening Test 14463-4, 14464-2, 14467-5, 14470-9, 14471-7, 14474-1, 14509-4, 14510-2, 14513-6, 16600-9, 21189-6, 21190-4, 21191-2, 21613-5, 23838-6, 31771-9, 31772-7, 31777-6, 36902-5, 36903-3, 42931-6, 43304-5, 43404-3, 43405-0, 43406-8, 44806-8, 44807-6, 45067-6, 45068-4, 45069-2, 45070-0, 45076-7, 45078-3, 45080-9, 45084-1, 45091-6, 45095-7, 45098-1, 45100-5, 47211-8, 47212-6, 49096-1, 4993-2, 50387-0, 53925-4, 53926-2, 557-9, 560-3, 6349-5, 6354-5, 6355-2, 6356-0, 6357-8, 80360-1, 80361-9, 80362-7

Childhood Immunization Series (CIS)		
Percentage of children age 2 who had vaccine series completed on or before their 2 nd birthday.		
CPT/CPT II		
DTaP (4 doses) 90698, 90700, 90721, 90723 Hep A (1 dose) 90633 Hep B (3 doses) 90723, 90740, 90744, 90747-48 HiB (3 doses) 90644-48, 90698, 90721, 90748 Influenza (2 doses) 90655, 90657, 90661-62, 90673, 90685-88 IPV (3 doses) 90698, 90713, 90723 MMR (1 dose) 90707, 90710 Measles/Rubella (1 dose) 90708 Measles (1 dose) 90705 Mumps (1 dose) 90704 Rubella (1 dose) 90706 PCV (4 doses) 90669-70 Rotavirus (2-3 doses) 90680-81 VZV (1 dose) 90710, 90716		
CVX Codes		
DTaP (4 doses) 20, 50, 106, 107, 110, 120 Hep A (1 dose) 31, 83, 85 Hep B (3 doses) 08, 44, 45, 51, 110 HiB (3 doses) 17, 46-51, 120, 148 Influenza (2 doses) 88, 135, 140, 141, 150, 153, 155, 158, 161 PV (3 doses) 10, 89, 110, 120 MMR (1 dose) 03, 94 Measles/Rubella (1 dose) 04 Measles (1 dose) 05 Mumps (1 dose) 07 Rubella (1 dose) 06 PCV (4 doses) 100, 133, 152 Rotavirus (2-3 doses) 2 dose: 119 3 dose: 116, 122 VZV (1 dose) 21, 94		
HCPCS	ICD-10 Diagnosis	SNOMED CT
Hep B (3 doses) G0010 Influenza (2 doses) G0008 PCV (4 doses) G0009	Hep B (3 doses) 3E0234Z	PCV (4 doses) 448964007

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Colorectal Cancer Screening (COL)		
Percentage of members ages 50-74 who had an appropriate screening for colorectal cancer.		
CPT/CPT II	HCPCS	LOINC
Colonoscopy 44388-94, 44397, 4401-08, 45355, 45378-93, 45398 Computed Tomography (CT) 74261-63 FIT-DNA Test Flexible Sigmoidoscopy 45330-35, 45337-42, 45345-47, 45349-50 FOBT 82270, 82274	Colonoscopy G0105, G0121 Flexible Sigmoidoscopy G0104 FOBT G0328 FIT-DNA Test G0464 (retired 01.01.16)	FIT-DNA Test 77353-1, 77354-9 FOBT 12503-9, 12504-7, 14563-1, 14564-9, 14565-6, 2335-8, 27396-1, 27401-9, 27925-7, 27926-5, 29771-3, 56490-6, 56491-4, 57905-2, 58453-2, 77353-1, 77354-9, 80372-6

Risk of Continued Opioid Use (COU)			
Percentage of members 18 and older who have a new episode of opioid use that puts them at risk for continued opioid use.			
Opioid Medications			
<ul style="list-style-type: none"> • Butorphanol • Codeine • Dihydrocodeine • Fentanyl 	<ul style="list-style-type: none"> • Hydrocodone • Hydromorphone • Levorphanol • Meperidine 	<ul style="list-style-type: none"> • Methadone • Morphine • Opium • Oxycodone 	<ul style="list-style-type: none"> • Oxymorphone • Pentazocine • Tapentadol • Tramadol

Appropriate Testing for Children with Pharyngitis (CWP)		
Percentage of children ages 3-18 who were diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.		
CPT/CPT II	LOINC	ICD-10 Diagnosis
Group A Strep Test 87070-71, 87081, 87430, 87650-52, 87880	Group A Strep Test 11268-0, 17656-0, 17898-8, 18481-2, 31971-5, 49610-9, 5036-9, 60489-2, 626-	Pharyngitis J02.0, J02.8, J02.9, J03.00, J03.01, J03.80-81, J03.90-91

	2, 6557-3, 6558-1, 6559-9, 68954-7, 78012-2
--	---

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)	
Percentage of emergency department (ED) visits for members 13 years and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence, who had a follow-up visit for AOD.	
CPT/CPT II	ICD-10 Diagnosis
Stand-Alone Visits 98960-62, 99078, 99201-05, 99211-15, 99217-20, 99241-45, 99341-45, 99347-49, 99350, 99384-87, 99394-97, 99401-04, 99408-09, 99411-12, 99510 Telehealth Modifier 95, GT Telephone Visits 98967, 98968, 99441, 99442, 99443 Online Assessments 98969, 99444	AOD Abuse and Dependence F10.10, F10.120, F10.121, F10.129, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230
Scenario 1	
CPT/CPT II AND	Place of Service Codes/Location
Group Visits 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76	02, 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 52, 53, 57, 71, 72
Scenario 2	
CPT/CPT II AND	Place of Service Codes/Location
Group Visits 99221-23, 99231-33, 99238-39, 99251-55	02, 52, 53

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Follow-Up After Hospitalization for Mental Illness (FUH)	
Percentage of discharges for members ages 6 and older who were hospitalized for treatment of select mental illness diagnoses and had a follow-up visit with a mental health practitioner.	
Scenario 1	
CPT/CPT II	CPT/CPT II Modifier
Stand-Alone Visits 98960-62, 99078, 99201-05, 99211-15, 99217-20, 99241-45, 99341-45, 99347-50, 99383-87, 99393-97, 99401-04, 99411-12, 99510	Telehealth Modifier 95, GT
HCPCS	CPT/CPT II Modifier
Stand-Alone Visits G0155, G0176-77, G0409-11, G0463, H0002, H0004, H0031, H0034-37, H0039-40, H2000-01, H2010-20, M0064, S0201, S9480, S9484-85, T1015	Telehealth Modifier 95, GT
Scenario 2	
CPT/CPT II AND	Place of Service Codes/Location
Mental Health Visit 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90867-70, 90875-76	02, 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18 19, 20, 22, 33, 49, 50, 52, 53, 71, 72
Scenario 3	
CPT/CPT II AND	Place of Service Codes/Location
Mental Health Visit 99221-23, 99231-33, 99238-39, 99251-55	02, 52, 53
Scenario 4	
UBREV	
Behavioral Health Care Setting 0513, 0900-05, 0907, 0911-17, 0919	

Scenario 5
UBREV
Non-behavioral Health Care Setting 0510, 0515-17, 0519-23, 0526-29, 0982-83
Scenario 6
UBREV
Non-behavioral Health Care Setting 0510, 0515-17, 0519-23, 0526-29, 0982-83
Scenario 7
CPT/CPT II
Transitional Care 99495-96

Follow-Up After Emergency Department Visit for Mental Illness (FUM)		
Percentage of emergency department (ED) visits for members 6 years and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness.		
CPT/CPT II	HCPCS	UBREV
Visit Setting Unspecified 90791, 90792, 90832, 90833, 90834, 90836, 90837, 90838, 90839, 90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221, 99222	Partial Hospitalization/Intensive Outpatient G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485	Partial Hospitalization/Intensive Outpatient 0905, 0907, 0912, 0913 Electroconvulsive therapy 0901
Telehealth modifier 95, GT		
Observation 99217, 99218, 99219, 99220		
Electroconvulsive therapy 90870		
POS		ICD-10 PCS
Outpatient 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 71, 72		Electroconvulsive Therapy GZB0ZZZ,

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Partial Hospitalization 52 Community Mental Health Center 53 Telehealth 02 Ambulatory Surgical Center 24	GZB1ZZZ, GZB2ZZZ, GZB3ZZZ, GZB4ZZZ
---	---------------------------------------

Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)

Percentage of adolescent and adult members with a new episode of alcohol or other drug (AOD) abuse or dependence who received AOD treatment.		
CPT/CPT II	HCPCS	UBREV
Stand-Alone Visits 98960-62, 99078, 99201-05, 99211-15, 99217-20, 99241-45, 99341-45, 99347-49, 99350, 99384-87, 99394-97, 99401-04, 99408-09, 99411-12, 99510	Stand-Alone Visits G0155, G0176, G0177, G0396, G0397, G0409, G0410, G0411, G0443, G0463, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0022, H0031, H0034, H0035, H0036, H0037, H0039, H0040, H0047, H2000, H2001, H2010, H2011, H2012, H2013, H2014, H2015, H2016, H2017, H2018, H2019, H2020, H2035, H2036, M0064, S0201, S9480, S9484, S9485, T1006, T1012, T1015	Stand-Alone Visits 0510, 0513, 0515, 0516, 0517, 0519, 0520, 0521, 0522, 0523, 0526, 0527, 0528, 0529, 0900, 0902, 0903, 0904, 0905, 0906, 0907, 0911, 0912, 0913, 0914, 0915, 0916, 0917, 0919, 0944, 0945, 0982, 0983

Scenario 1

CPT/CPT II AND	Place of Service Codes/Location
Group Visits 90791-92, 90832-34, 90836-40, 90845, 90847, 90849, 90853, 90875-76	02, 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 33, 49, 50, 52, 53, 57, 71, 72

Scenario 2

CPT/CPT II AND	Place of Service Codes/Location
Group Visits 99221-	02, 52, 53

23, 99231-33, 99238-39, 99251-55	
----------------------------------	--

Immunizations for Adolescents (IMA)

Percentage of adolescents age 13 who had at least 2 HPV, 1 MCV, and 1 Tdap vaccine on or before their 13 th birthday.	
CPT/CPT II	CVX Codes
HPV 90649-51 Tdap 90715 Td 90714, 90718 MCV 90734	HPV 62, 118, 137, 165 Tdap 115 MCV 108, 136, 147

Use of Imaging Studies for Low Back Pain (LBP)

Percentage of members with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.	
CPT/CPT II	UBREV
Imaging Studies 72010, 72020, 72052, 72100, 72110, 72114, 72120, 72131-33, 72141-42, 72146-49, 72156, 72158, 72200, 72202, 72220	Imaging Studies 0320, 0329, 0350, 0352, 0359, 0610, 0612, 0614, 0619, 0972

Medication Management for People with Asthma (MMA)

Percentage of members ages 5-64 during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period.	
Asthma Controller Medications	
Antiasthmatic combinations	<ul style="list-style-type: none"> •Dyphylline-guaifenesin •Guaifenesin-theophylline
Antibody inhibitors	<ul style="list-style-type: none"> •Omalizumab
Anti-interleukin-5	<ul style="list-style-type: none"> •Mepolizumab •Reslizumab
Inhaled steroid combinations	<ul style="list-style-type: none"> •Budesonide-formoterol •Fluticasone-vilanterol •Fluticasone-salmeterol •Mometasone-formoterol

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Inhaled corticosteroids	•Beclomethasone •Budesonide	•Ciclesonide •Flunisolide	•Fluticasone • Mometasone
Leukotriene modifiers	•Montelukast	•Zafirlukast	•Zileuton
Methylxanthines	•Dyphylline	•Theophylline	
Asthma Reliever Medications			
Short-acting, inhaled beta-2 agonists	•Albuterol •Levalbuterol	•Pirbuterol	

Medication Reconciliation Post-Discharge (MRP)
Percentage of discharges from Jan. 1 – Dec. 1 of the measurement year for members ages 18 or older for whom medications were reconciled on the date of discharge through 30 days after discharge (31 days total).
CPT/CPT II
Medication Reconciliation 1111F Office Visit 99495-96

Osteoporosis (OMW)		
Percentage of women ages 67-85 who suffered a fracture and who had either a bone mineral density test or prescription for a drug to treat osteoporosis with six months of the fracture.		
CPT/CPT II	HCPCS	ICD-10 Procedure
BMD Tests 76977, 77078, 77080-82, 77085-86	BMD Tests G0130 Osteoporosis Medications J0630, J0897, J1740, J3110, J3487, J3488, J3489, Q2051	BMD Tests BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1, BP4NZZ1, BP4PZZ1, BQ00ZZ1, BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BR00ZZ1, BRO7ZZ1, BRO9ZZ1, BROGZZ1

Pregnancy and Postpartum Care (PPC)	
Percentage of women who had a live birth that received a prenatal care visit in the first trimester or within 42 days of enrollment. Percentage of women who had a live birth that had a postpartum visit on or between 21 and 56 days after delivery.	
CPT/CPT II	
Prenatal Bundled Services 59400, 59425-26, 59510, 59610, 59618 Stand-Alone Prenatal Visits 99500, 0500F-02F Prenatal Visits 99201-05, 99211-15, 99241-45 Obstetric Panel 80055, 80081 Prenatal US 76081, 76805, 76811, 76813, 76815-21, 76825-28 ABO Group 86900 Rh Type 86901	Cytomegalovirus Antibody 86644 Herpes Simplex Antibody 86694-96 Rubella Antibody 86762 Toxoplasma Antibody 86777-78 Postpartum Bundled Services 59400, 59410, 59510, 59515, 59610, 59614, 59618, 59622 Postpartum Visits 57170, 58300, 59430, 99501, 0503F Cervical Cytology 88141-43, 88147-48, 88150, 88152-54, 88164-67, 88174-75
HCPCS	
Prenatal Bundled Services H1005 Stand-Alone Prenatal Visits H1000, H1001, H1002, H1003, H1004 Prenatal Visits G0463, T1015	Postpartum Visits G0101 Cervical Cytology G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091
ICD-10 Procedure	
Prenatal Ultrasound BY49ZZZ, BY4BZZZ, BY4CZZZ, BY4DZZZ, BY4FZZZ, BY4GZZZ	Postpartum Visits Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2
LOINC	
ABO Group 57743-7, 883-9 Rh Type 10331-7, 1305-2, 34961-3, 972-0, 978-7 ABO Group and Rh Type 77397-8, 882-1, 884-7 Cytomegalovirus Antibody 13225-8, 13949-3, 15377-5, 16714-8, 16715-5, 16716-3, 22239-8, 22241-4, 22244-8, 22246-3, 22247-1, 22249-7, 24119-0, 30325-5, 32170-	44480-2, 44494-3, 44507-2, 45210-2, 47230-8, 48784-3, 49848-5, 50758-2, 51915-7, 51916-5, 5202-7, 5203-5, 5204-3, 5205-0, 5206-8, 5207-6, 5208-4, 5209-2, 5210-0, 52977-6, 52981-8, 53377-8, 53560-9, 57321-2, 73559-7, 7907-9, 7908-7, 7909-5, 7910-3, 7911-1, 7912-9, 7913-7, 9422-7

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

<p>3, 32791-6, 32835-1, 45326-6, 47307-4, 47363-7, 47430-4, 49539-0, 5121-9, 5122-7, 5124-3, 5125-0, 5126-8, 5127-6, 52976-8, 52984-2, 59838-3, 78445-4, 7851-9, 7852-7, 7853-5, 9513-3</p> <p>Herpes Simplex Antibody 10350-7, 13323-1, 13324-9, 13501-2, 13505-3, 14213-3, 16942-5, 16944-1, 16949-0, 16950-8, 16954-0, 16955-7, 16957-3, 16958-1, 17850-9, 17851-7, 19106-4, 21326-4, 21327-2, 22339-6, 22341-2, 22343-8, 24014-3, 25435-9, 25837-6, 25839-2, 26927-4, 27948-9, 30355-2, 31411-2, 32687-6, 32688-4, 32790-8, 32831-0, 32834-4, 32846-8, 33291-6, 34152-9, 34613-0, 36921-5, 40466-5, 40728-8, 40729-6, 41149-6, 41399-7, 42337-6, 42338-4, 43028-0, 43030-6, 43031-4, 43111-4, 43180-9, 44008-1,</p>	<p>Rubella Antibody 13279-5, 13280-3, 17550-5, 22496-4, 22497-2, 24116-6, 25298-1, 25420-1, 25514-1, 31616-6, 34421-8, 40667-8, 41763-4, 43810-1, 49107-6, 50694-9, 51931-4, 52986-7, 5330-6, 5331-4, 5332-2, 5333-0, 5334-8, 5335-5, 63462-6, 8013-5, 8014-3, 8015-0</p> <p>Toxoplasma Antibody 11598-0, 12261-4, 12262-2, 13286-0, 17717-0, 21570-7, 22577-1, 22580-5, 22582-1, 22584-7, 23485-6, 23486-4, 23784-2, 24242-0, 25300-5, 25542-2, 33336-9, 34422-6, 35281-5, 35282-3, 40677-7, 40678-5, 40697-5, 40785-8, 40786-6, 42949-8, 47389-2, 47390-0, 5387-6, 5388-4, 5389-2, 5390-0, 5391-8, 56990-5, 56991-3, 8039-0, 8040-8, 83123-0</p> <p>Cervical Cytology 1 5024-7, 18500-9, 19762-4, 19764-0, 19765-7, 19766-5, 19774-9, 33717-0, 47527-7, 47528-5</p>
UBREV	
Prenatal Visits 0514	
Cervical Cytology 0923	

Phenothiazine antipsychotics	<ul style="list-style-type: none"> • Chlorpromazine • Fluphenazine • Perphenazine 	<ul style="list-style-type: none"> • Perphenazine-amitriptyline • Prochlorperazine 	<ul style="list-style-type: none"> • Thioridazine • Trifluoperazine
Thioxanthenes	<ul style="list-style-type: none"> • Thiothixene 		
Oral Antipsychotic Combination Medications			
Psychotherapeutic combinations		<ul style="list-style-type: none"> • Amitriptyline-perphenazine 	
Long-Acting Injection Medications			
14 day supply	<ul style="list-style-type: none"> • Risperidone 		
28 day supply	<ul style="list-style-type: none"> • Aripiprazole • Fluphenazine decanoate • Haloperidol decanoate 	<ul style="list-style-type: none"> • Olanzapine • Paliperidone palmitate 	

Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	
Percentage of members 18-64 with schizophrenia and cardiovascular disease who had a low-density lipoprotein cholesterol (LDL-C) test during the measurement year.	
CPT/CPT II	LOINC
LDL-C Test 80061, 83700-01, 83704, 83721, 3048F-50F	LDL-C Test 12773-8, 13457-7, 18261-8, 18262-6, 2089-1, 49132-4, 55440-2

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)			
Percentage of members ages 19-64 during the measurement year with schizophrenia who were dispensed and remained on an antipsychotic medication for at least 80 percent of the treatment period.			
Oral Antipsychotic Medications			
Miscellaneous antipsychotic agents	<ul style="list-style-type: none"> • Aripiprazole • Asenapine • Brexpiprazole • Cariprazine • Clozapine • Haloperidol 	<ul style="list-style-type: none"> • Iloperidone • Loxapine • Lurasidone • Molindone • Olanzapine • Paliperidone 	<ul style="list-style-type: none"> • Pimozide • Quetiapine • Quetiapine fumarate • Risperidone • Ziprasidone

Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD)	
Percentage of members ages 18-64 with schizophrenia and diabetes who had both an HbA1c test and a low-density lipoprotein cholesterol (LDL-C) test during the measurement year.	
CPT/CPT II	LOINC
HbA1c Test 83036-37, 3044F-46F LDL-C Test 80061, 83700-01, 83704, 83721, 3048F-50F	HbA1c Test 17856-6, 4548-4, 4549-2 LDL-C Test 12773-8, 13457-7, 18261-8, 18262-6, 2089-1, 49132-4, 55440-2

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	
Percentage of members ages 18-64 with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.	
CPT/CPT II	LOINC
Glucose Test 80047-48, 80050, 80053, 80069, 82947, 82950-51 HbA1c Test 83036-37, 3044F-46F	Glucose Test 10450-5, 1492-8, 1494-4, 1496-9, 1499-3, 1501-6, 1504-0, 1507-3, 1514-9, 1518-0, 1530-5, 1533-9, 1554-5, 1557-8, 17865-7, 20436-2, 20437-0, 20438-8, 20440-4, 26554-6, 41024-1, 6749-6, 9375-7 HbA1c Test 17856-6, 4548-4, 4549-2

Use of Opioids from Multiple Providers (UOP)			
Proportion of members 18 years and older, receiving prescription opioids for ≥15 days during the measurement year who received opioids from multiple providers and/or multiple pharmacies.			
Opioid Medications			
<ul style="list-style-type: none"> • Butorphanol • Codeine • Dihydrocodeine • Fentanyl 	<ul style="list-style-type: none"> • Hydrocodone • Hydromorphone • Levorphanol • Meperidine 	<ul style="list-style-type: none"> • Methadone • Morphine • Opium • Oxycodone 	<ul style="list-style-type: none"> • Oxymorphone • Pentazocine • Tapentadol • Tramadol

Transitions of Care (TRC)	
Percentage of discharges for members 18 years of age and older who had each of the following during the measurement year: notification of inpatient admission (no coding), receipt of discharge information (no coding), patient engagement after inpatient discharge, medication reconciliation post-discharge.	
CPT/CPT II	
Office Visit 99495-96 Medication Reconciliation 1111F	

Well-Child Visits in the First 15 Months (W15)		
Percentage of members who turned 15 months old during the measurement year and had six or more well-child visits with a primary care provider during their first 15 months of life.		
CPT/CPT II	HCPCS	ICD-10 Diagnosis
Well-Care Visits 99381-85, 99391-95, 99461	Well-Care Visits G0438, G0439	Well-Care Visits Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.5, Z00.8, Z02.0, Z02.1, Z02.2, Z02.3, Z02.4, Z02.5, Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9

Use of Opioids at High Dosage (UOD)			
Proportion of members 18 years of age and older, receiving prescription opioids for ≥15 days during the measurement year at a high dosage (average milligram morphine dose [MME] >120 mg).			
Opioid Medications			
<ul style="list-style-type: none"> • Butorphanol • Codeine • Dihydrocodeine • Fentanyl 	<ul style="list-style-type: none"> • Hydrocodone • Hydromorphone • Levorphanol • Meperidine 	<ul style="list-style-type: none"> • Methadone • Morphine • Opium • Oxycodone 	<ul style="list-style-type: none"> • Oxymorphone • Pentazocine • Tapentadol • Tramadol

Well-Child Visits in the 3 rd , 4 th , 5 th , and 6 th Years (W34)		
Percentage of members ages 3-6 who had one or more well-child visits with a primary care provider during the measurement year.		
CPT/CPT II	HCPCS	ICD-10 Diagnosis
Well-Care Visits 99381-85, 99391-95, 99461	Well-Care Visits G0438, G0439	Well-Care Visits Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.5, Z00.8, Z02.0, Z02.1, Z02.2, Z02.3, Z02.4, Z02.5, Z02.6, Z02.71, Z02.79, Z02.81, Z02.82, Z02.83, Z02.89, Z02.9

*Codes in green close member care opportunity.

HEDIS® CODING OPPORTUNITIES

Weight Assessment and Counseling (WCC)		
Percentage of members ages 3-17 who had an outpatient visit with a primary care provider of OB/GYN and had evidence of the following during the measurement year: BMI, counseling for nutrition, counseling for physical activity.		
CPT/CPT II	HCPCS	ICD-10 Diagnosis
Nutrition 97802-04	Nutrition G0270, G0271, G0447, S9449, S9452, S9470 Physical Activity G0447 (mod 25), S9451	BMI % Z68.51, Z68.52, Z68.53, Z68.54 Nutrition Z71.3 Physical Activity Z02.5, Z71.82

Disclaimer: UnitedHealthcare will make the final determination regarding reimbursement upon receipt of a claim. Submitting a claim with a code included in this document is not a guarantee of payment. Payment of covered services is contingent upon coverage within an individual member's benefit plan, your eligibility for payment, any claim processing requirements, and your participation agreement with UnitedHealthcare.

CPT Category II codes with an asterisk will not close the care opportunity because they're not included in the National Committee for Quality Assurance (NCQA) HEDIS® technical specifications. However, please use CPT Category II codes because they provide valuable quality information when submitted with the appropriate billing code.

***Codes in green close member care opportunity.**